Altered cerebral blood flow as an early modifiable contributor to alzheimer's disease and related dementias alzheimer's disease (ad) and related dementias (ad/ADRD), the most common and debilitating…

Active Grant Awarded

Award ID
R01AG103824
Recipient
Awarding agency
Obligated
$655,883

Award facts

Assistance listing
93.866 Aging Research
Completion date 4% complete
Place of performance
Roslindale, MA 02131, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services' National Institute on Aging awarded Hebrew Rehabilitation Center, doing business as Hebrew Senior Life, $655,883 on September 17, 2026, as Grant R01AG103824 under the Aging Research program (CFDA 93.866). The project will test whether cumulative cardiac, vascular, and metabolic dysfunction jointly drive chronically declining cerebral blood flow (CBF), and whether CBF decline, potentially with distinct spatial patterns, contributes to cerebral small vessel disease and amyloid deposition in cognitively normal adults. The stated objectives are to identify long-term modifiable factors that influence CBF trajectories and to clarify CBF's role in the multifactorial etiology of Alzheimer's disease and related dementias to inform early detection and prevention. The project leverages the recipient's expertise in arterial spin labeling. Place of performance is Roslindale, Massachusetts (02131), and the ultimate completion date is May 31, 2031. The assistance type is grant. The Aging Research program funds biomedical, social, and behavioral research on the aging process, with the National Institute on Aging's mission emphasizing prevention and treatment of Alzheimer's disease and related dementias.

Description

Altered cerebral blood flow as an early modifiable contributor to alzheimer's disease and related dementias alzheimer's disease (ad) and related dementias (ad/ADRD), the most common and debilitating neurodegenerative disorders, affect millions of americans, yet preventive strategies remain limited. To date, only anti-amyloid therapy and intensive blood pressure (BP) control have demonstrated efficacy in preventing cognitive impairment underlying ad/ADRD. Further data from our sprint neuroimaging substudy demonstrate that intensive BP control also slows the progression of white matter hyperintensities, an established marker of cerebral small vessel disease (CSVD), and increases cerebral blood flow (CBF) in patients with hypertension. Accumulating evidence now links reduced CBF to ADRD risk and to key ad pathologies, such as amyloid deposition, supporting the potential of CBF as both a biomarker and a modifiable therapeutic target, complementary to amyloid-targeting molecular therapies. Despite this promise, we lack longitudinal studies tracking early, subclinical, and regional CBF changes to advance ADRD prevention, particularly in cognitively normal adults, where early pathophysiological changes may be most amenable to intervention. This project's objectives are to identify key long-term modifiable factors influencing CBF trajectories and to elucidate the role of CBF in the multifactorial etiology of ADRD to inform its early detection and prevention. The proposed research will test the central hypothesis that cumulative long-term cardiac, vascular, and metabolic dysfunction jointly lead to chronically declining CBF, and that CBF decline, potentially with distinct spatial patterns, contributes to both CSVD and amyloid deposition, which together accelerate cognitive decline and increase ADRD risk. This project leverages our expertise in arterial spin labeling (ASL) neuroimaging, brain imaging for ADRD, and vascular epidemiology, and our access to two complementary and well-characterized cohorts: the multi-ethnic study of atherosclerosis (MESA) and the rotterdam study (RS). The MESA cohort provides deep cardiometabolic profiling over 20 years and subsequent longitudinal assessments of brain MRI that include state-of-the-art ASL-based global and regional CBF, plasma ad biomarkers, and cognition. The RS provides longitudinal global CBF assessed by phase-contrast MRI and dementia follow-up over 20 years (N~3,500). The specific aims of this project are to: (1) identify major longterm determinants of late-life CBF trajectories; (2) elucidate regional CBF patterns linked to vascular and ad pathologies and early cognitive decline; and (3) determine how CBF trajectories predict dementia risk over 20 years. Because CBF alteration is potentially reversible and may precede structural brain injuries, our study, leveraging two unique cohorts with four decades of rich data, could enable earlier, targeted strategies to preserve and restore CBF for more effective dementia prevention.

Quick answers

Who received award R01AG103824?

R01AG103824 was awarded to Hebrew Rehabilitation Center by National Institute on Aging (National Institutes of Health) on September 17, 2026.

How much is award R01AG103824 worth?

$655,883 has been obligated on R01AG103824.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award